文献速递心力衰竭与心肌病血脂与心血管预防

PREVENT-HF方程在不同心衰亚型中的社区与门诊人群表现

Performance of the PREVENT-HF Equations Across Heart Failure Subtypes in Community-Based and Ambulatory Healthcare Samples.
PubMed 文献 · Circulation · 2026-11-02

本研究在五个社区队列和两个门诊电子病历样本中评估PREVENT-HF方程对10年新发HFrEF和HFpEF的预测性能。结果显示该方程对两种亚型均有良好区分度,且对HFpEF的区分度 consistently 优于HFrEF;校准度相似。由于方程原为总体心衰风险开发,亚型特异性阈值仍需未来研究确立。

要点

  • PREVENT-HF对HFpEF的区分度优于HFrEF,社区队列AUROC 0.824 vs 0.789。
  • 门诊电子病历样本中同样呈现HFpEF区分度更优的模式。
  • 两种亚型的校准度相似,社区队列ICI分别为0.041和0.038。

核心结论

  • PREVENT-HF方程对HFpEF和HFrEF均有优秀区分度,且对HFpEF的区分度 consistently 优于HFrEF,校准度相似;亚型特异性阈值需未来研究。

研究设计与样本

  • 汇总五个纵向队列研究(基线1989-2013)及两个纵向初级保健电子病历样本(BIDMC基线2004-2014;MGB基线2001-2018)。
  • 纳入30-79岁无 prevalent 心血管疾病或心衰的成人:汇总队列23,652人,BIDMC 29,815人,MGB 138,999人。

主要发现

  • 汇总队列中1,232人发生心衰(HFpEF 432例[35%],HFrEF 522例[42%]);BIDMC中259人(1%)发生心衰(HFpEF 133例[51%],HFrEF 101例[39%]);MGB中1,050人发生心衰(HFpEF 586例[56%],HFrEF 381例[36%])。
  • 汇总队列AUROC:HFpEF 0.824(95%CI 0.807,0.839) vs HFrEF 0.789(95%CI 0.770,0.807);BIDMC:0.897(95%CI 0.874,0.918) vs 0.833(95%CI 0.791,0.869);MGB:0.864(95%CI 0.848,0.880) vs 0.797(95%CI 0.771,0.820)。
  • AP/事件率比值:汇总队列HFpEF 2.92(95%CI 2.47,3.54) vs HFrEF 2.66(95%CI 2.33,3.14);BIDMC 8.08(95%CI 6.12,12.30) vs 5.12(95%CI 3.84,8.17);MGB 6.84(95%CI 5.66,8.28) vs 4.12(95%CI 3.37,5.16)。
  • 校准度相似,例如汇总队列ICI:HFpEF 0.041(95%CI 0.039,0.043),HFrEF 0.038(95%CI 0.036,0.040)。

临床怎么用

  • PREVENT-HF可用于社区和门诊人群的总体心衰风险预测,对HFpEF的区分能力尤其突出。
  • 临床解读时应知晓其对HFrEF的区分度略低,且目前尚无亚型特异性风险阈值。

局限性

  • PREVENT-HF原为总体心衰风险开发,非亚型特异性,亚型风险阈值未建立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PREVENT-HF equations estimate 10-year risk of overall heart failure (HF), inclusive of both HF with preserved and reduced ejection fraction (HFpEF; HFrEF). Given differential risk factor profiles, pathophysiology, and therapeutic strategies for each HF subtype, we sought to examine the performance of PREVENT-HF for subtype-specific risk assessment. METHODS: We included data from five pooled longitudinal cohort studies (baseline exam 1989 to 2013) and two longitudinal primary-care electronic health record-based samples (Beth Israel Deaconess Medical Center [BIDMC], baseline 2004 to 2014; Mass General Brigham [MGB], baseline 2001 to 2018). We assessed the performance of the PREVENT-HF equations in predicting 10-year incident HFrEF and HFpEF, including model discrimination (area under the receiver operating characteristic curve [AUROC]; average precision [AP]/event rate) and calibration (integrated calibration index [ICI]), in adults aged 30-79 years without prevalent cardiovascular disease or HF. RESULTS: The pooled cohort studies included 23,652 (55% women, age 60 ± 13 years), of whom 1,232 developed HF (432 [35%] HFpEF, 522 [42%] HFrEF). The BIDMC sample included 29,815 (55% women, 50 ± 13 years), of whom 259 (1%) developed HF (133 [51%] HFpEF, 101 [39%] HFrEF). MGB included 138,999 (62% women, 52 ± 13 years), of whom 1050 developed HF (586 [56%] HFpEF, 381 [36%] HFrEF). PREVENT-HF demonstrated better discrimination for HFpEF than HFrEF across all samples: in the pooled cohorts, the AUROC for HFpEF was 0.824 (95% CI 0.807, 0.839) versus 0.789 (95% CI 0.770, 0.807) for HFrEF; in BIDMC, the AUROC for HFpEF was 0.897 (95% CI 0.874, 0.918) versus 0.833 (95% CI 0.791, 0.869) for HFrEF; in MGB, the AUROC for HFpEF was 0.864 (95% CI 0.848, 0.880) versus 0.797 (95% CI 0.771, 0.820) for HFrEF. Similar results were reflected in the AP/event rate ratios: 2.92 (95% CI 2.47, 3.54) for HFpEF compared to 2.66 (95% CI 2.33, 3.14) for HFrEF in the pooled cohorts; 8.08 (95% CI 6.12, 12.30) for HFpEF compared to 5.12 (95% CI 3.84, 8.17) for HFrEF in BIDMC; and 6.84 (95% CI 5.66, 8.28) for HFpEF compared to 4.12 (95% CI 3.37, 5.16) for HFrEF in MGB. Calibration was similar for HFpEF and HFrEF across samples. For example, in the pooled cohorts, the ICI for HFpEF was 0.041 (95% CI 0.039, 0.043) and for HFrEF was 0.038 (95% CI 0.036, 0.040). CONCLUSIONS: PREVENT-HF demonstrated excellent discrimination for both HF subtypes across community-based cohorts and real-world samples, with consistently better discrimination for HFpEF as compared to HFrEF. Given PREVENT-HF was developed to estimate overall HF risk rather than subtype-specific risk, future studies are needed to establish subtype-specific risk thresholds.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Mounsey LA, Wang D, Ribeiro PH, et al. Performance of the PREVENT-HF Equations Across Heart Failure Subtypes in Community-Based and Ambulatory Healthcare Samples. Circulation. 2026. PMID: 42969101. doi:10.1161/CIRCULATIONAHA.126.083383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。